Other Species / Isoforms
  Securin (human)      LTP 

LTP (Low Throughput Papers) : The number of records in which this modification site was determined using methods other than discovery mass spectrometry.

  HTP 

HTP (High Throughput Papers): The number of records in which this modification site was assigned using ONLY proteomic discovery mass spectrometry.

 
Y6-p
__MATLIyVDkENGE
0 2
Securin (human) __MATLIyVDkENGE Y6-p
Securin (mouse) __MATLIFVDKDNEE F6
Securin (rat) __MATLIFVDKDNEE F6
K9-ub
ATLIyVDkENGEPGt
Downstream
1 1
Effects on Modified Protein
  • protein degradation
Securin (human) ATLIyVDkENGEPGt K9-ub
Securin (mouse) ATLIFVDKDNEEPGR K9
Securin (rat) ATLIFVDKDNEEPGS K9
T16-p
kENGEPGtRVVAKDG
0 1
Securin (human) kENGEPGtRVVAKDG T16-p
Securin (mouse) KDNEEPGRRLASKDG R16
Securin (rat) KDNEEPGSRLASKDG S16
S28-p
KDGLKLGsGPsIKAL
0 3
Securin (human) KDGLKLGsGPsIKAL S28-p
Securin (mouse) KDGLKLGTGVKALDG T28
Securin (rat) KDGLKLGSGVkALDG S28
S31-p
LKLGsGPsIKALDGR
Upstream
Downstream
1 6
Effects on Modified Protein
  • enzymatic activity, induced
  • protein degradation
  • ubiquitination
Effects on Biological Processes:
  • chromatin organization, altered
Putative in vivo kinases:
  • CAMK2A (human)
Regulatory protein:
  • PPP2CA (human)
Treatment
  • KN-93
Securin (human) LKLGsGPsIKALDGR S31-p
Securin (mouse) gap -
Securin (rat) gap -
K33
LGsGPsIKALDGRsQ
0 1
Securin (human) LGsGPsIKALDGRsQ K33
Securin (mouse) LKLGTGVKALDGKLQ K31
Securin (rat) LKLGSGVkALDGKLQ K31-ac
S39-p
IKALDGRsQVstPRF
0 2
Securin (human) IKALDGRsQVstPRF S39-p
Securin (mouse) VKALDGKLQVSTPRV L37
Securin (rat) VkALDGKLQVSTPRV L37
S42-p
LDGRsQVstPRFGkT
0 5
Securin (human) LDGRsQVstPRFGkT S42-p
Securin (mouse) LDGKLQVSTPRVGKV S40
Securin (rat) LDGKLQVSTPRVGKV S40
T43-p
DGRsQVstPRFGkTF
0 11
Securin (human) DGRsQVstPRFGkTF T43-p
Securin (mouse) DGKLQVSTPRVGKVF T41
Securin (rat) DGKLQVSTPRVGKVF T41
K48-ac
VstPRFGkTFDAPPA
0 2
Securin (human) VstPRFGkTFDAPPA K48-ac
Securin (mouse) VSTPRVGKVFNAPAV K46
Securin (rat) VSTPRVGKVFGAPGL K46
K48-ub
VstPRFGkTFDAPPA
Downstream
1 3
Effects on Modified Protein
  • protein degradation
Securin (human) VstPRFGkTFDAPPA K48-ub
Securin (mouse) VSTPRVGKVFNAPAV K46
Securin (rat) VSTPRVGKVFGAPGL K46
T60-p
PPALPKAtRKALGtV
Downstream
1 0
Effects on Modified Protein
  • molecular association, regulation
Securin (human) PPALPKAtRKALGtV T60-p
Securin (mouse) APAVPKASRKALGTV S57
Securin (rat) APGLPKASRKALGTV S57
T66-p
AtRKALGtVNRATEK
Upstream
Downstream
1 1
Effects on Modified Protein
  • enzymatic activity, induced
  • protein degradation
  • ubiquitination
Effects on Biological Processes:
  • chromatin organization, altered
Putative in vivo kinases:
  • CAMK2A (human)
Regulatory protein:
  • PPP2CA (human)
Treatment
  • KN-93
Securin (human) AtRKALGtVNRATEK T66-p
Securin (mouse) ASRKALGTVNRVAEK T63
Securin (rat) ASRKALGTVNRVTEk T63
K73
tVNRATEKSVKTKGP
0 1
Securin (human) tVNRATEKSVKTKGP K73
Securin (mouse) TVNRVAEKPMKTGKP K70
Securin (rat) TVNRVTEkPVKSSkP K70-ac
G79
EKSVKTKGPLKQKQP
0 1
Securin (human) EKSVKTKGPLKQKQP G79
Securin (mouse) EKPMKTGKPLQPKQP K76
Securin (rat) EkPVKSSkPLQSKQP K76-ac
S87-p
PLKQKQPsFsAKKMT
Upstream
Downstream
1 4
Effects on Modified Protein
  • enzymatic activity, induced
  • protein degradation
  • ubiquitination
Effects on Biological Processes:
  • chromatin organization, altered
Putative in vivo kinases:
  • CAMK2A (human)
Regulatory protein:
  • PPP2CA (human)
Treatment
  • ischemia
  • KN-93
Securin (human) PLKQKQPsFsAKKMT S87-p
Securin (mouse) PLQPKQPTLTGKKIT T84
Securin (rat) PLQSKQPTLSVKKIT T84
S89-p
KQKQPsFsAKKMTEK
Upstream
Downstream
1 2
Effects on Modified Protein
  • enzymatic activity, induced
  • protein degradation
  • ubiquitination
Effects on Biological Processes:
  • chromatin organization, altered
Putative in vivo kinases:
  • CAMK2A (human)
Regulatory protein:
  • PPP2CA (human)
Treatment
  • KN-93
Securin (human) KQKQPsFsAKKMTEK S89-p
Securin (mouse) QPKQPTLTGKKITEK T86
Securin (rat) QSKQPTLSVKKITEK S86
V98
KKMTEKTVKAkSSVP
0 1
Securin (human) KKMTEKTVKAkSSVP V98
Securin (mouse) KKITEKStKTQsSVP T95-p
Securin (rat) KKITEKSTKTQGSAP T95
K101-ub
TEKTVKAkSSVPASD
0 4
Securin (human) TEKTVKAkSSVPASD K101-ub
Securin (mouse) TEKStKTQsSVPAPD Q98
Securin (rat) TEKSTKTQGSAPAPD Q98
S102
EKTVKAkSSVPASDD
0 1
Securin (human) EKTVKAkSSVPASDD S102
Securin (mouse) EKStKTQsSVPAPDD S99-p
Securin (rat) EKSTKTQGSAPAPDD G99
Y111-p
VPASDDAyPEIEKFF
0 18
Securin (human) VPASDDAyPEIEKFF Y111-p
Securin (mouse) VPAPDDAYPEIEKFF Y108
Securin (rat) APAPDDAYPEIEKFF Y108
S165-p
LFQLGPPsPVKMPsP
Upstream
Downstream
2 51
Effects on Modified Protein
  • molecular association, regulation
  • phosphorylation
  • protein stabilization
Effects on Biological Processes:
  • carcinogenesis, altered
  • signaling pathway regulation
  • transcription, induced
Putative upstream phosphatases:
  • PPP2CA (human)
Treatment
  • dasatinib
  • ischemia
  • LB-100
  • LRRK2-IN-1
  • nocodazole
  • okadaic_acid
  • PI-103
  • siRNA
view more >
Securin (human) LFQLGPPsPVKMPsP S165-p
Securin (mouse) LLHLGPPsPLKTPFL S162-p
Securin (rat) LLHLDPPsPLQKPFL S162-p
S171-p
PsPVKMPsPPWESNL
Upstream
Downstream
1 1
Effects on Modified Protein
  • molecular association, regulation
  • phosphorylation
  • protein stabilization
Effects on Biological Processes:
  • carcinogenesis, altered
  • signaling pathway regulation
  • transcription, induced
Putative upstream phosphatases:
  • PPP2CA (human)
Treatment
  • LB-100
  • okadaic_acid
  • siRNA
view more >
Securin (human) PsPVKMPsPPWESNL S171-p
Securin (mouse) PsPLKTPFLSWESDP F168
Securin (rat) PsPLQKPFLPWESDP F168
S183-p
SNLLQSPssILSTLD
Upstream
Downstream
1 0
Effects on Modified Protein
  • protein degradation
Effects on Biological Processes:
  • cell cycle regulation
Kinase, in vitro:
  • GSK3B (human)
Putative in vivo kinases:
  • GSK3B (human)
Treatment
  • nocodazole
Securin (human) SNLLQSPssILSTLD S183-p
Securin (mouse) SDPLYSPPSALSTLD P180
Securin (rat) SDPLPSPPSALSALD P180
S184-p
NLLQSPssILSTLDV
Upstream
Downstream
1 0
Effects on Modified Protein
  • protein degradation
Effects on Biological Processes:
  • cell cycle regulation
Kinase, in vitro:
  • GSK3B (human)
Putative in vivo kinases:
  • GSK3B (human)
Treatment
  • nocodazole
Securin (human) NLLQSPssILSTLDV S184-p
Securin (mouse) DPLYSPPSALSTLDV S181
Securin (rat) DPLPSPPSALSALDV S181